Recalls and Safety Alerts: Caution on Gadolinium-Containing Contrast Agents in Patients with Renal Failure
Published by Food and Drug Adminstration (FDA): Patient Safety July 31st, 2006 in Patient Safety, Regulatory AffairsFDA has learned of a rare, possibly fatal disease among patients with renal failure who underwent Magnetic Resonance Angiography (MRA) using Omniscan, a contrast agent containing gadolinium. The disease is called Nephrogenic Systemic Fibrosis/ Nephr…